Company intelligence / Profile preview
Gradalis, Inc.
Dallas, Texas, United Statesgradalisinc.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Vigil is the first cellular immunotherapy to demonstrate longer-term survival benefits in a randomized controlled trial of patients with solid tumors. Phase 2b results have been published in Lancet Oncology and presented at the American Society of Clinical Oncology. The FDA has designated Vigil as a Regenerative Medicine Advanced Therapy (RMAT) for patients with HRP ovarian cancer and high cTMB based on statistically significant and clinically meaningful improvement in overall survival.[2][3][5]
- Therapeutic areas
- Oncology
- Modalities
- Personalized immunotherapycellular immunotherapybi-shRNAi technology
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Beyond the preview
Go deeper on Gradalis, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gradalis, Inc..